Latest Biotech News

Two developments reshaped the sequencing and proteomics landscape: the Federal Circuit remanded Guardant Health’s patent dispute with TwinStrand to the Patent Trial and Appeal Board for further...

Regulators in Europe and the U.K. unveiled measures to accelerate multinational trial starts. The EU launched FAST‑EU, a voluntary pilot aiming for a 70‑day timeline from filing to trial start,...

Researchers at the Icahn School of Medicine at Mount Sinai reported IL‑12‑producing CAR T cells that directly target tumor‑associated macrophages (TAMs) and reset the immunosuppressive tumor...

Erasca announced the closing of an upsized public offering, selling 25,875,000 shares at $10.00 each and generating gross proceeds of roughly $258.8 million. The clinical‑stage precision oncology...

Corxel Pharmaceuticals closed a $287 million Series D round to push its oral small‑molecule GLP‑1 receptor agonist CX‑11 through Phase II and toward global development. The financing will support...

The FDA approved Guardant Health’s Guardant360 CDx as a companion diagnostic to identify BRAF V600E‑mutant metastatic colorectal cancer patients for Pfizer’s encorafenib plus cetuximab and...

NVIDIA and Eli Lilly announced a $1 billion partnership to build an AI‑powered drug discovery laboratory in the San Francisco Bay Area. The collaboration will combine NVIDIA’s computing and AI...

Bristol Myers Squibb entered a collaboration with Janux Therapeutics focused on Janux’s tumor‑activated T‑cell engager platform, paying $50 million upfront and leaving the deal worth up to roughly...

Corcept Therapeutics reported that relacorilant, its oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a Phase III ovarian cancer trial when added to chemotherapy....

Moderna told Bloomberg it is pulling back on investments in late‑stage vaccine trials in response to political backlash in the United States, shifting its R&D focus away from newer...

Genomics pioneer J. Craig Venter co‑founded Diploid Genomics, a new AI‑driven genomics analytics company backed by Healthier Capital, aiming to combine long‑read sequencing, imaging and AI to...

The National Institutes of Health announced it will stop supporting research using fetal human tissue, a move characterized by some scientists and advocacy groups as political rather than...

Swiss company 4bases and University of Florence launched clinical pilot studies to validate a nanopore‑based cytogenetics workflow, KaryoSolver, for rapid copy‑number variation detection in...

Erasca announced the closing of an upsized public offering that sold 25,875,000 shares at $10.00 each, including full exercise of the underwriters’ option. The company reported gross proceeds of...

Corxel Pharmaceuticals completed a $287 million Series D to advance CX‑11, an oral GLP‑1 receptor agonist licensed from Vincentage, through planned global Phase II and preparatory Phase III work....

NVIDIA and Eli Lilly announced a $1 billion collaboration to build an AI-powered drug discovery laboratory in the San Francisco Bay Area. The multi-year partnership will combine NVIDIA’s compute...

Guardant Health secured FDA approval for its Guardant360 CDx blood test as a companion diagnostic to identify BRAF V600E‑mutant metastatic colorectal cancer patients eligible for Pfizer’s...

Janux Therapeutics entered an exclusive collaboration and licensing agreement with Bristol Myers Squibb to develop tumor‑activated therapeutics derived from Janux’s TRACTr platform. Financial...

Corcept reported a 35% reduction in risk of death when relacorilant was added to chemotherapy in platinum‑resistant ovarian cancer, meeting an overall survival endpoint in the Phase III study. The...

Researchers at the Icahn School of Medicine at Mount Sinai developed IL‑12‑producing CAR‑T cells that target tumor‑associated macrophages (TAMs) rather than cancer cells directly. In aggressive...